Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
| Market Cap (Intraday) | 402.14M |
| Current PE | 5.63 |
| Forward PE | 5.56 |
| 2yr Forward PE | 10.24 |
| 10-Day MA | $4.06 |
| 50-Day MA | $3.82 |
| 200-Day MA | $3.83 |
Catalyst Pharmaceuticals, Inc. Stock, NASDAQ:CPRX
355 Alhambra Circle, Suite 1250, Coral Gables, Florida 33134
United States of America
Phone: +1.305.420.3200
Number of Employees: 76
Description
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.